Empaken 10

Description

Empaken– Empagliflozin 10mg/ 25mg
• Empaken is an SGLT2 inhibitor
• Empaken reduces reabsorption of filtered glucose
from the tubular lumen and lowers the renal
threshold for glucose (RTG).
• Empaken is preferred as an additional antidiabetic
agent or alternative first–line agent in patients
• Empaken has proven cardiovascular and renal
benefits

Therapeutic Use T2DM treatment either as;
• First line
• Add– on
Heart Failure– add on for CV protection
Proven benefits
• Reduced MI, stroke, CHF hospitalization and
cardiovascular death
• Reduced risk of kidney disease, reduced worsening
of kidney disease